EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer

Neil E Fleshner iD, Rui M Bernardino iD, Jonathan Izawa, Darrel Drachenberg, Jeff W Saranchuk, Adrian Fairey, Simon Tanguay iD, Michael Leveridge, Fred Saad iD, Rodney H Breau, Bobby Shayegan iD, Laurence Klotz und 22 weitere

Journal of Clinical Oncology · 2025-12 · 43 (34) · 3662-3671

DOI: 10.1200/jco-25-01070 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-12. Verfasst von Neil E Fleshner und 33 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Metformin, Prostatic Neoplasms, Watchful Waiting, Hypoglycemic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Active surveillance (AS) is a standard management strategy for low-risk prostate cancer (PCa), but a significant proportion of patients ultimately experience disease progression. Metformin, a commonly prescribed antidiabetic agent, has demonstrated antitumor activity in preclinical studies and observational data, prompting investigation into its potential to delay PCa progression. PATIENTS AND METHODS The Metformin Active Surveillance Trial (MAST) was a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of metformin in men with low-risk, localized PCa managed with AS. Eligible participants were randomly assigned 1:1 to receive either metformin (850 mg twice daily) or placebo and were followed for up to 36 months. The primary end point was time to progression, defined as therapeutic and/or pathologic progression. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS A total of 408 patients were randomly assigned (205 metformin, 203 placebo). After a median follow-up of 36 months, 144 participants experienced progression (70 metformin, 74 placebo), with no significant difference in PFS (hazard ratio [HR], 1.09 [95% CI, 0.79 to 1.52]; P = .59). Negative biopsy rates at 36 months were 41.0% (metformin) versus 31.1% (placebo; P = .181). In prespecified subgroup analysis, metformin was associated with increased pathologic progression among obese patients (BMI ≥ 30; HR, 2.36 [95% CI, 1.21 to 4.59]; P = .0092). CONCLUSION Metformin did not reduce progression in men with low-risk PCa on AS. The observed adverse effect in obese patients merits further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminProstatic NeoplasmsWatchful WaitingHypoglycemic AgentsHumansMaleAgedDouble-Blind MethodMiddle AgedProgression-Free SurvivalDisease Progression

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • University of Western Ontario, London, ON, Canada.
  • Manitoba Prostate Cancer, University of Manitoba, Winnipeg, MB, Canada.
  • CancerCare Manitoba, Winnipeg, MB, Canada.
  • Northern Alberta Urology Clinic, Edmonton, AB, Canada.
  • McGill University Health Center, Montreal, QC, Canada.

ORCID-Profile: Neil E Fleshner, Rui M Bernardino, Simon Tanguay, Fred Saad, Bobby Shayegan, Sunakshi Chowdhary, Tiiu Sildva, Shabbir M H Alibhai, Jessica G Cockburn, Joan Sweet, Clare O'Connell, Doron Berlin, Robert J Hamilton, Patrick O Richard, Anthony M Joshua

Zitieren

APA

Fleshner, N. E., Bernardino, R. M., Izawa, J., Drachenberg, D., Saranchuk, J. W., Fairey, A., Tanguay, S., Leveridge, M., Saad, F., Breau, R. H., Shayegan, B., Klotz, L., Hersey, K., Chowdhary, S., Chadwick, K., Wagner, H., Sildva, T., Alibhai, S. M. H., Rastegar, N., …, & Joshua, A. M. (2025). Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. Journal of Clinical Oncology, 43(34), 3662-3671. https://doi.org/10.1200/jco-25-01070

Vancouver

Fleshner NE, Bernardino RM, Izawa J, Drachenberg D, Saranchuk JW, Fairey A, et al. Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. Journal of Clinical Oncology. 2025;43(34):3662-3671. doi:10.1200/jco-25-01070

BibTeX
@article{Fleshner2025,
  author = {Fleshner, Neil E and Bernardino, Rui M and Izawa, Jonathan and Drachenberg, Darrel and Saranchuk, Jeff W and Fairey, Adrian and Tanguay, Simon and Leveridge, Michael and Saad, Fred and Breau, Rodney H and Shayegan, Bobby and Klotz, Laurence and Hersey, Karen and Chowdhary, Sunakshi and Chadwick, Karen and Wagner, Heidi and Sildva, Tiiu and Alibhai, Shabbir M H and Rastegar, Naghmeh and Kenk, Miran and Veloso, Rosette and Cockburn, Jessica G and Sweet, Joan and O'Connell, Clare and Kapusta, Linda and Kubendran, Aingeshaan and Azizi, Tabassom and Berlin, Doron and Hamilton, Robert J and Lajkosz, Katherine and van der Kwast, Theodorus and Rendon, Ricardo A and Richard, Patrick O and Joshua, Anthony M},
  title = {Metformin Active Surveillance Trial in Low-Risk Prostate Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {34},
  pages = {3662--3671},
  doi = {10.1200/jco-25-01070}
}
Kostenlos starten →